The cost-effectiveness of lipid lowering for primary cardiovascular prevention in chronic kidney disease: moving beyond statins.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 31229030.
- Also identified by DOI 10.1016/j.kint.2019.02.029.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Because of high risk of cardiovascular disease, patients with chronic kidney disease may benefit from cholesterol-lowering therapy beyond statins. A cost-effectiveness analysis of adding ezetimibe to high-dose statins for primary cardiovascular disease prevention in patients with non-dialysis-dependent chronic kidney disease found treatment with ezetimibe to be cost-effective for many patients with chronic kidney disease. We describe the importance of this topic and explain key assumptions necessary for the investigators to arrive at their conclusions.
Medical subject headings
- Cardiovascular Diseases
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Renal Insufficiency, Chronic